Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
In June 2021, the agency approved Wegovy (semaglutide 2.4 mg once weekly) for weight management in adults with a body mass index (BMI) of 30 kg/m or greater (obesity), or a BMI of 27 kg/m or greater (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea
Wegovy 25 mg tablets Summary of Product Characteristics (Reference only)
Chao AM, Wadden TA, Berkowitz RI, Quigley K, Silvestry F
Our umbrella evidence synthesis and grading suggest that GLP-1RAs may partially meet this need
US$ 26.73
US$ 28.08
US$ 27.03
